CRISPR Therapeutics
About
What does CRISPR Therapeutics do?
CRISPR Therapeutics is a Swiss-American biotechnology company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines for serious diseases. They develop cures for genetic diseases by precisely modifying DNA, with a diverse portfolio including treatments for hemoglobinopathies, oncology, and regenerative medicine. Their lead program, exagamglogene autotemcel (exa-cel), has received regulatory approval in several countries for sickle cell disease and transfusion-de…
What is CRISPR Therapeutics's revenue?
StartupHub estimates CRISPR Therapeutics's annual revenue at $110.2M (range $26.8M to $245.7M, 34% confidence), based on comparable companies in the sector.
What is CRISPR Therapeutics's valuation?
StartupHub estimates CRISPR Therapeutics's effective valuation at $629.5M (range $226.1M to $1.2B, 56% confidence), based on comparable companies in the sector.
How much funding has CRISPR Therapeutics raised?
CRISPR Therapeutics has raised a total of $547M in funding. The most recent round on record is Series B.
Where is CRISPR Therapeutics headquartered?
CRISPR Therapeutics is headquartered in Zug, Switzerland.
When was CRISPR Therapeutics founded?
CRISPR Therapeutics was founded in 2013.
What industry does CRISPR Therapeutics operate in?
CRISPR Therapeutics operates in Biotechnology, Gene Editing, Therapeutics, Pharmaceuticals.
No comments yet. Be the first to share your take.